Skip to main content
OpenTrials
Completed

NCT Number: NCT01073033

Oral Supplement for Pregnant and Lactating Mothers

To assess protection against early life infections through supplementation of mothers during pregnancy to the newborns' growth, morbidity, immune status intra and extra-uterine.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Ospital Ng Muntinlupa

Manila, Philippines

About this study

During pregnancy mothers have to fulfill the tremendous physiological needs to support their own immune status as well as that of their babies. Accordingly, it appears highly valuable to provide mothers with a nutritional supplement during pregnancy and lactation to promote the immune development in newborns, thus reinforcing the infants' defenses.

In that respect, an appropriate maternal diet must provide sufficient energy and nutrients to meet the mother's usual requirements and promote health status, as well as the needs of the growing fetus and beyond for the neonate.

Key organogenesis steps take place during fetal life and many functional features of the immune system are already coded in the genetic asset of the individual. However, at birth the immune system remains fairly immature. An epigenetic, postnatal instruction seems to be extremely important for the maturation of the immune system allowing its full functionality.

The cross-talk between the mother and her baby is, indeed, crucial for the optimal development of the foetus and subsequently for the full and functional maturation of the neonate.

The newborn relies for his protection almost exclusively on his innate immune system that is initially instructed and educated early in life by factors derived from his mother as well as post-natal environmental factors such as early life colonization with micro-organisms that activates the innate immunity and enhance Th1-cell polarization thereby potentially reducing atopic dermatitis with respect to the hygiene hypothesis.

A large part of this immune education is provided by factors transmitted from the mother pre-natally through the placenta or post-natally via the breast milk. Breast milk contains a number of nutrients and bioactive components, including immune cells, maternal antibodies (mainly secretory IgA), cytokines, growth factors, lactoferrin, nucleotides, triacylglycerols, fatty acids, oligosaccharides, and vitamins. All together, these components beneficially impact the health status of the newborn, conferring, among other functions, immune education and early protection.

A typical example of such transfer of immune competence is the TGF-β that could be transmitted in active from either through the placenta or absorbed by the neonates through the milk. This TGF-β is an important IgA switch factor and this is likely to be responsible, in part, for the capacity of breast-fed infant to produce higher levels of mucosal SIgA compared to non-breast fed infants. Moreover, milk soluble CD14 transmitted to the newborn contributes to prime the neonatal gut to modulate the microbial recognition and establishment of endogenous microbiota.

Diarrhea episodes are major manifestation of common infant infections of viral or bacterial aetiology and are a key health concern in paediatrics. As mentioned above there are evidences that some probiotic strains significantly improve diarrheal outcomes in infants, particularly rotavirus diarrhea. In that respect diarrhea occurrence was selected as the primary outcome in the present trial.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Expecting mothers who are in their 6th month of pregnancy
  • Willing to consume 2 x 200 ml of test product daily
  • Willing to exclusively breastfeed until the baby is at least 2-month old
  • Having signed the informed consent

Exclusion criteria

  • Known allergy to cow's milk
  • Subjects previously diagnosed HIV(+) and Hepatitis B (+)
  • Multiple pregnancy
  • High risk pregnancy (pre-eclampsia, diabetes, etc)
  • Currently participating or having participated in another clinical trial during the last 3 months
  • Subjects who consumed pro- and /or prebiotics-containing food/supplement* in the month before inclusion

Treatment and study plan

milk supplement 1

Dietary Supplement

milk supplement with probiotics

Other names: Suitable for pregnant and lactating period.

milk supplement 2

Dietary Supplement

milk supplement without probiotics

Other names: Suitable for pregnant and lactating periode.

Primary outcomes

  1. The incidence of diarrhea in infants from birth to 1 year

    Time frame: 24 months

Secondary outcomes

  1. In infants: growth, morbidity, immune maturation, metabolomics profile

    Time frame: 18 months

  2. In mothers: fetal growth, general health, immune system, metabolomics profile and preterm delivery

    Time frame: 18 months

Sponsors and collaborators

Lead sponsor

Société des Produits Nestlé (SPN)

Industry

Collaborators

  • University of the Philippines

Registry information

Official study title

Oral Supplement for Pregnant and Lactating Mothers to Promote Infant Immune Maturation and Protection Against Early Life Infections

Important dates

Study start
2010
Primary completion
2012
Study completion
2012
First posted
Feb 22, 2010
Registry last updated
Sep 27, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.